A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Summary

This is a phase 2 study (the second phase in testing a new drug) to see how useful an investigational drug called afatinib is in patients with advanced cancer with changes in the HER gene. Afatinib is a drug that is approved by Health Canada for the treatment of advanced lung cancer with changes in the HER gene. Afatinib works by attaching to and blocking a protein called HER from working. HER is an important protein that contributes to the growth of cancer cells.

Timeline

Start

2015-08

Primary completion

2023-05-04

Completion

2023-05-04

Publications

• Salawu A, Hansen AR, Spreafico A, Al-Ezzi E, Webster S, Bedard PL, Doi J, Wang L, Siu LL, Abdul Razak AR. A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. Target Oncol. 2022 May;17(3):271-281. doi: 10.1007/s11523-022-00884-z. Epub 2022 May 30.

Drugs

Indications